RUA Life Sciences Past Earnings Performance

Past criteria checks 2/6

RUA Life Sciences's earnings have been declining at an average annual rate of -3.5%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 26.3% per year. RUA Life Sciences's return on equity is 2.6%, and it has net margins of 7.1%.

Key information

-3.5%

Earnings growth rate

6.3%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate26.3%
Return on equity2.6%
Net Margin7.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

Feb 15
The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

Revenue & Expenses Breakdown

How RUA Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:RUA Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243021
30 Jun 243-121
31 Mar 242-121
31 Dec 232-221
30 Sep 232-231
30 Jun 232-231
31 Mar 232-231
31 Dec 222-231
30 Sep 222-231
30 Jun 222-221
31 Mar 222-221
31 Dec 212-230
30 Sep 212-230
30 Jun 212-230
31 Mar 212-130
31 Dec 201-120
30 Sep 201-120
30 Jun 201-120
31 Mar 200-110
31 Dec 191-110
30 Sep 191-110
30 Jun 190-110
31 Mar 190-110
31 Dec 180010
30 Sep 180010
30 Jun 180010
31 Mar 180000
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 161010
30 Sep 161010
30 Jun 161010
31 Mar 161010
30 Sep 150-110
30 Jun 150010
31 Mar 151010
30 Sep 141010
30 Jun 140010
31 Mar 140010

Quality Earnings: RUA has a high level of non-cash earnings.

Growing Profit Margin: RUA became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RUA has become profitable over the past 5 years, growing earnings by -3.5% per year.

Accelerating Growth: RUA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RUA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (39.9%).


Return on Equity

High ROE: RUA's Return on Equity (2.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 05:27
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RUA Life Sciences plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew Murray DarleyCavendish
Christopher DonnellanCavendish
Christopher DonnellanCavendish Historical (Cenkos Securities)